Unicycive Therapeutics, Inc. — Form 8-K
Filed November 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Unicycive's NDA resubmission for oxylanthanum carbonate (OLC) was accepted by the FDA with a PDUFA target action date of March 25, 2027, following a Complete Response Letter in June 2026 citing manufacturing deficiencies—not efficacy/safety concerns. The company has $59M in cash as of September 30, 2026, with expected runway beyond 2027. CMS issued favorable reimbursement rules (permanent phosphate binder funding of $12.85 per treatment effective January 1, 2027), and Unicycive believes OLC qualifies for two-year transitional drug add-on payment (TDAPA) if approved.
Why this rating
NDA acceptance is a critical regulatory milestone for a $64M-market-cap biotech with one lead asset. Approval March 2027 could transform commercial trajectory and cash runway viability. CMS reimbursement clarity is favorable. However, FDA approval is not guaranteed.
Tradability signal
NO TRADE
No trade: already up 4.6% on the news and the fade evidence is too weak. Similar past filings (508 in this cell) moved -0.04% in the called direction over 4 hrs; shrunk for sample size that's a -0.04% edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $3.64 | +10 min · unknown $3.65 ▲ 0.25% | +30 min · unknown $3.73 ▲ 2.34% | +1 hr · unknown $3.77 ▲ 3.52% | +4 hrs · unknown $3.63 ▼ 0.41% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.